Aventis Pasteur ready to meet nation's needs for tetanus and diphtheria vaccine

June 20, 2002

Swiftwater, PA - June 20, 2002 - Aventis Pasteur announced today that it has produced a sufficient supply of the adult and adolescent vaccine for tetanus and diphtheria, Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (Td), to meet the nation's critical care and routine booster needs. According to the June 21, 2002, issue of the U.S. Centers for Disease Control and Prevention's (CDC) Morbidity & Mortality Weekly Report (MMWR), this increase in supply has prompted the CDC to lift its year-long deferral, enabling physicians to now provide patients with routine Td boosters.

"Aventis Pasteur has been working for the past year to successfully end the national shortage of Td vaccine," said Michael Decker, MD, MPH, vice president, scientific and medical affairs at Aventis Pasteur. "Aventis Pasteur's efforts to relieve the shortage is an indication of the company's ability to meet the nation's need for Td vaccine now and in the future."

"With the return of ample tetanus and diphtheria vaccine supply, people who were asked to delay Td boosters during the last year should schedule appointments with their doctors to catch up," said William Schaffner, MD, professor and chairman, department of preventive medicine at Vanderbilt University and a national expert in infectious diseases. "Furthermore, anyone who can't remember the last time they received a Td booster should call their doctor and ask if they are due to receive a booster."

Immunization is the best way to protect against tetanus and diphtheria infection in the United States since both diseases are vaccine-preventable. Adults and adolescents require a booster shot every 10 years throughout life to maintain protection against tetanus and diptheria. Almost all reported cases of tetanus are in persons who have either never been vaccinated, or who completed a primary series, but have not had a booster in the preceeding 10 years . A recent study showed that less than half of Americans 20 years and older have adequate protection against both tetanus and diphtheria2.

The combination Td vaccine should be given to adults and adolescents and is not the same vaccine that is given to protect infants and children against diphtheria, tetanus and pertussis as part of the childhood immunization series.

Aventis Pasteur became the primary national supplier of the tetanus and diphtheria vaccine last year when another manufacturer abruptly withdrew from the market. Since then, Aventis Pasteur increased production capacity so that it could supply the national market. During the shortage, the company worked closely with the CDC and medical organizations to ensure that tetanus vaccine always remained available for critical needs.

Health care providers can place orders for Td vaccine online at www.vaccineshoppe.com or by calling 1-800-VACCINE (1-800-822-2463).
-end-
Aventis: A World Leader in Pharmaceuticals
Tetanus and Diphtheria Toxoids Adsorbed for Adult Use is produced and marketed by Aventis Pasteur Inc., which is located in Swiftwater, PA, and is a subsidiary of Aventis Pasteur SA. Aventis Pasteur Inc. provides the broadest range of human vaccines and biologicals commercially available from any single U.S. vaccine company. It is a leading supplier of vaccines to protect against influenza, diphtheria, tetanus, pertussis, polio, Japanese encephalitis, yellow fever, Haemophilus influenzae type b disease, meningitis, rabies, and typhoid fever.

Aventis Pasteur, a world leader in vaccines with the broadest range of products, produces more than one billion doses of vaccines every year to immunize 400 million people around the world. Aventis Pasteur, headquartered in Lyon, France, is a subsidiary of Aventis SA.

Aventis (NYSE: AVE) is dedicated to improving life by treating and preventing human disease through the discovery and development of innovative pharmaceutical products. Aventis focuses on prescription drugs for important therapeutic areas such as oncology, cardiology, diabetes and respiratory disorders as well as on human vaccines. In 2001, Aventis generated sales of 17.7 billion euros ($15.5 billion), invested approximately 3 billion euros ($2.6 billion) in research and development and employed approximately 75,000 people in its core business. Aventis corporate headquarters are in Strasbourg, France. For more information, please visit: www.aventis.com.

Statements in this news release other than historical information are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the availability of resources, the timing and effects of regulatory actions, the strength of competition, the outcome of litigation, and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Report on Form 20-F of Aventis on file with the Securities and Exchange Commission.

(Note to Editors: Full prescribing information is available)

US Press Contacts:
Len Lavenda
Aventis Pasteur
570-839-4446


Taryn Green
Cooney Waters Group
212-886-2200

Cooney Waters Group, Inc.

Related Vaccine Articles from Brightsurf:

Who should get the COVID-19 vaccine first?
Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution -- called the Fair Priority Model -- which aims to reduce premature deaths and other irreversible health consequences from COVID-19.

Breakthrough with cancer vaccine
Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers.

How to improve the pneumococcus vaccine
Pneumococcus kills 1 million children annually according to the World Health Organization.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Successful MERS vaccine in mice may hold promise for COVID-19 vaccine
In a new study, published April 7 in mBio, researchers from the University of Iowa and the University of Georgia demonstrate that a new vaccine fully protects mice against a lethal dose of MERS, a close cousin of COVID-19.

Coronavirus Vaccine: Where are we and what's next? (video)
You might have heard that COVID-19 vaccine trials are underway in Seattle.

Why isn't there a vaccine for staph?
A study from Washington University School of Medicine in St.

Exposing vaccine hesitant to real-life pain of diseases makes them more pro-vaccine
New research from Brigham Young University professors finds there is a better way to help increase support for vaccinations: Expose people to the pain and suffering caused by vaccine-preventable diseases instead of trying to combat people with vaccine facts.

Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.

On the horizon: An acne vaccine
A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine.

Read More: Vaccine News and Vaccine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.